CA-TALKDESK
Talkdesk®, Inc. , a global customer experience leader for customer-obsessed companies, has been selected by LifeSearch, the UK’s leading life insurance broker, as its contact centre solution provider. A Talkdesk-powered contact centre will be at the heart of a full-scale digital transformation of LifeSearch operations, allowing for a uniquely personal experience for any customer, any time, anywhere.
Over the last 24 years, LifeSearch has become the UK’s leading life insurance broker, helping families protect the lives they love, as well as plan compassionately for the dark moments that may come. Working with the biggest UK insurance brands and partnering with some of the UK’s biggest price comparison websites, LifeSearch has protected more than 750,000 families and insured over a million lives.
Talkdesk CX Cloud™ , an end-to-end customer experience solution, will be the cornerstone of a new contact centre approach for LifeSearch – and that contact centre evolution will pave the path towards larger digital transformation for the company. Previously, the LifeSearch contact centre relied on a mixture of platforms and technologies that were retrofitted over time. The Talkdesk solution represents the first large-scale investment in true enterprise technology purpose built to provide a modernised contact centre that can sustainably grow with LifeSearch at scale. Talkdesk Virtual Agent™ for both digital and voice will help streamline workflows and improve routing efficiencies, as LifeSearch blends inbound and outbound activities for a more seamless customer journey. AI-powered features like Talkdesk Interaction Analytics™ and Talkdesk QM Assist™ will offer valuable, real-time coaching opportunities to help agents make every customer interaction one in which the customer feels supported by a trusted adviser.
“We advise customers on some of the most important financial decisions they will make, protecting themselves and their families. These aren’t conversations that can be scripted or pulled from a playbook – every customer interaction will have different requirements,” said Chris Neilson, chief technology officer, LifeSearch. “The Talkdesk solution will give LifeSearch advisers and customer support colleagues the best tools to leverage customer insights and data, so we can provide each new and existing customer with a bespoke experience unique to their circumstances.”
“Trust and value are now more relevant for consumers arranging insurance. Automation, better experiences for both customers and agents, and the creation of new business models are all driving forces behind the current digital transformation within the insurance industry,” said Kieran King, chief customer officer, Talkdesk. “With the Talkdesk solution, LifeSearch is transforming the customer experience for the families they protect. We’re proud to partner with LifeSearch in evolving and exceeding their customer experience goals.”
Additional Resources
- See Talkdesk recognized as a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service
- Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centres
Social Networks
- Web: https://www.talkdesk.com/customer-community/
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact centre leader for customer-obsessed companies. Our automation-first customer experience solutions optimise our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.
About LifeSearch
Over 24 years, LifeSearch has grown into the UK’s biggest life insurance specialist, offering expert, independent advice to customers around life insurance, critical illness cover, income protection, family income benefit, serious illness cover and business insurance. Over our two-plus-decades, LifeSearch has picked up dozens of awards for company culture, expertise and customer service. We have a TrustPilot score of 4.9 out of 5 (excellent) and came Top #3 in our debut appearance on the Sunday Times’ list of Best Places to Work in the UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AppLogic Networks Announces Strategic Rollout of Industry-First, Comprehensive 400GE Networking Enablement Across Virtual and Appliance-Based Network Domains to Meet Explosive Data Growth8.7.2025 15:00:00 CEST | Press release
Innovative solution represents cost-efficient, streamlined offering with multiple deployment options, catering to both physical networking appliances and virtual infrastructure, while delivering superior performanceEnables Tier 1 and Tier 2 fixed and mobile network operators to accelerate deployment, simplify maintenance, and scale without the need for massive infrastructure investment AppLogic Networks, a leader in application classification and high-performance software-based networking solutions, today announced a significant expansion of its portfolio to support 400 Gigabit Ethernet (400GE) across both traditional appliance-based and virtual infrastructure domains. This move comes as telecom and service providers worldwide face unprecedented growth in network traffic, fueled by 4K/8K streaming, cloud gaming, AI workloads, and IoT proliferation. As part of this expansion, AppLogic Networks now offers comprehensive 400GE enablement and interoperability in its flagship data plane plat
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom